Cancer Immunotherapy, 2nd Edition

  • Published By:
  • ISBN-10: 0123946336
  • ISBN-13: 9780123946331
  • DDC: 616.994061
  • Grade Level Range: College Freshman - College Senior
  • 684 Pages | eBook
  • Original Copyright 2013 | Published/Released June 2014
  • This publication's content originally published in print form: 2013

  • Price:  Sign in for price



There has been major growth in understanding immune suppression mechanisms and its relationship to cancer progression and therapy. This book highlights emerging new principles of immune suppression that drive cancer, and it offers radically new ideas about how therapy can be improved by attacking these principles. Following work that firmly establishes immune escape as an essential trait of cancer, recent studies have now defined specific mechanisms of tumor immune suppression. It also demonstrates how attacking tumors with molecular targeted therapeutics or traditional chemotherapeutic drugs can produce potent anti-tumor effects in preclinical models. This book provides basic, translational, and clinical cancer researchers with an indispensable overview of immune escape as a critical trait in cancer and how applying specific combinations of immunotherapy and chemotherapy to attack this trait may radically improve the treatment of advanced disease.

Table of Contents

Front Cover.
Half Title.
Title Page.
Copyright Page.
1: Introduction.
2: Principles of Basic Immunology.
3: Components of the Immune System.
4: Adaptive Immunity Adaptive Immunity:B Cells and Antibodies.
5: Adaptive Immunity:T Cells and Cytokines.
6: Dendritic Cells:Antigen Processing and Presentation.
7: Mucosal Immunity.
8: Principles of Cancer Immunobiology.
9: Cancer Immunoediting:From Surveillance to Escape.
10: Immunosurveillance:Innate and Adaptive Antitumor Immunity.
11: Immunological Sculpting:Natural Killer-Cell Receptors and Ligands.
12: Th17 Cells in Cancer.
13: Immune Escape:Immunosuppressive Networks.
14: Introduction to Cancer Therapeutics.
15: Principles of Cytotoxic Chemotherapy.
16: Pharmacokinetics and Safety Assessment.
17: Monoclonal Antibodies for Cancer Therapy and Prevention:Paradigm Studies in Targeting the neu/ERBB2/HER2 Oncoprotein.
18: Genetic Vaccines against Cancer:Design, Testing and Clinical Performance.
19: Comprehensive Immunomonitoring to Guide the Development of Immunotherapeutic Products for Cancer.
20: Strategies of Passive and Active Immunotherapy.
21: Adoptive T-cell Therapy:Engineering T-cell Receptors.
22: Dendritic Cell Vaccines Dendritic Cell Vaccines:Sipuleucel-T and Other Approaches.
23: Antibodies to Stimulate Host Immunity: Lessons from Ipilimumab.
24: Recombinant TRICOM-based Therapeutic Cancer Vaccines:Lessons Learned.
25: Adjuvant Strategies for Vaccines.
26: Improving Immunotherapeutic Responses.
27: Epigenetic Approaches:Emerging Role of Histone Deacetylase Inhibitors in Cancer Immunotherapy.
28: Molecular Profiling of Immunotherapeutic Resistance.
29: Immune Stimulatory Features of Classical Chemotherapy.
30: Immunotherapy and Cancer Therapeutics:A Rich Partnership.
31: Targeting Strategies to Defeat Immune Suppression.
32: JAK/STAT Signaling in Myeloid Cells; Targets for Cancer Immunotherapy.
33: Tumor-associated Macrophages in Cancer Growth and Progression.
34: Tumor-induced Myeloid-derived Suppressor Cells.
35: HyperAcute Vaccines:A Novel Cancer Immunotherapy.
36: Tumor Exosomes and Their Impact on Immunity and Cancer Progression.
37: Galectins:Key Players in the Tumor Microenvironment.
38: IDO in Immune Escape:Regulation and Therapeutic Inhibition.
39: IDO Pathway:effect on Foxp3+ Tregs and Cancer.
40: Arginase, Nitric Oxide Synthase, and Novel Inhibitors of L-arginine Metabolism in Immune Modulation.